Resultats de la cerca - Stella, Peter

Pharmaceutical pricing, cost containment and new treatments for rare diseases in children per Stella, Peter, Gold-von Simson, Gabrielle

Obtenir text complet Obtenir text complet Obtenir text complet

Prediction of Resuscitation for Pediatric Sepsis from Data Available at Triage per Stella, Peter, Haines, Elizabeth, Aphinyanaphongs, Yindalon

Obtenir text complet Obtenir text complet

Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice per Hidvégi, Tibor, Balogh, Zoltán, Vass, Viktor, Kovács, Gábor, Stella, Péter

Obtenir text complet Obtenir text complet Obtenir text complet

Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study per Mathieu, Chantal, Weisnagel, S. John, Stella, Peter, Bruhwyler, Jacques, Alexandre, Kathy

Obtenir text complet Obtenir text complet Obtenir text complet

Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis per Twigg, Stephen M., Escalada, Javier, Stella, Peter, Merino-Trigo, Ana, Lavalle-Gonzalez, Fernando J., Cariou, Bertrand, Meneghini, Luigi F.

Obtenir text complet Obtenir text complet Obtenir text complet

Validation of parsimonious prognostic models for patients infected with COVID-19 per Harish, Keerthi, Zhang, Ben, Stella, Peter, Hauck, Kevin, Moussa, Marwa M, Adler, Nicole M, Horwitz, Leora I, Aphinyanaphongs, Yindalon

Obtenir text complet Obtenir text complet Obtenir text complet

Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA per Mauricio, Dídac, Meneghini, Luigi, Seufert, Jochen, Liao, Laura, Wang, Hongwei, Tong, Liyue, Cali, Anna, Stella, Peter, Carita, Paulo, Khunti, Kamlesh

Obtenir text complet Obtenir text complet Obtenir text complet

Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-Worl... per Gupta, Shaloo, Wang, Hongwei, Skolnik, Neil, Tong, Liyue, Liebert, Ryan M., Lee, Lulu K., Stella, Peter, Cali, Anna, Preblick, Ronald

Obtenir text complet Obtenir text complet Obtenir text complet

The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type... per Yale, Jean-François, Pettus, Jeremy Hodson, Brito-Sanfiel, Miguel, Lavalle-Gonzalez, Fernando, Merino-Trigo, Ana, Stella, Peter, Chevalier, Soazig, Buzzetti, Raffaella

Obtenir text complet Obtenir text complet Obtenir text complet

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score... per Tabák, Ádám G., Anderson, John, Aschner, Pablo, Liu, Minzhi, Saremi, Aramesh, Stella, Peter, Tinahones, Francisco J., Wysham, Carol, Meier, Juris J.

Obtenir text complet Obtenir text complet Obtenir text complet

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (ED... per Roussel, Ronan, d'Emden, Michael C., Fisher, Miles, Ampudia‐Blasco, F. Javier, Stella, Peter, Bizet, Florence, Cali, Anna M. G., Wysham, Carol H.

Obtenir text complet Obtenir text complet Obtenir text complet

The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting per Meneghini, Luigi F., Mauricio, Didac, Orsi, Emanuela, Lalic, Nebojsa M., Cali, Anna M.G., Westerbacka, Jukka, Stella, Peter, Candelas, DEA, Christophe, Pilorget, Valerie, Perfetti, Riccardo, Khunti, Kamlesh

Obtenir text complet Obtenir text complet Obtenir text complet

Urinary NGAL Marks Cystic Disease in HIV-Associated Nephropathy per Paragas, Neal, Nickolas, Thomas L., Wyatt, Christina, Forster, Catherine S., Sise, Meghan, Morgello, Susan, Jagla, Bernd, Buchen, Charles, Stella, Peter, Sanna-Cherchi, Simone, Carnevali, Maria Luisa, Mattei, Silvia, Bovino, Achiropita, Argentiero, Lucia, Magnano, Andrea, Devarajan, Prasad, Schmidt-Ott, Kai M., Allegri, Landino, Klotman, Paul, D'Agati, Vivette, Gharavi, Ali G., Barasch, Jonathan

Obtenir text complet Obtenir text complet Obtenir text complet

A validated, real-time prediction model for favorable outcomes in hospitalized COVID-19 patients per Razavian, Narges, Major, Vincent J., Sudarshan, Mukund, Burk-Rafel, Jesse, Stella, Peter, Randhawa, Hardev, Bilaloglu, Seda, Chen, Ji, Nguy, Vuthy, Wang, Walter, Zhang, Hao, Reinstein, Ilan, Kudlowitz, David, Zenger, Cameron, Cao, Meng, Zhang, Ruina, Dogra, Siddhant, Harish, Keerthi B., Bosworth, Brian, Francois, Fritz, Horwitz, Leora I., Ranganath, Rajesh, Austrian, Jonathan, Aphinyanaphongs, Yindalon

Obtenir text complet Obtenir text complet Obtenir text complet